Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma
Department of Internal Medicine Y, Sutaria R, Patel P, Department of Rheumatology Y, Danve A. Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma. European Journal Of Rheumatology 2019, 6: 153-154. PMID: 30986169, PMCID: PMC6668642, DOI: 10.5152/eurjrheum.2019.18159.Peer-Reviewed Original ResearchMetastatic melanomaCheckpoint inhibitorsMyasthenia gravisAutoimmune myositisCombination of ipilimumabCytotoxic T lymphocytesCombination therapyT lymphocytesImmune responseAdverse effectsMelanomaNumerous immuneIpilimumabNivolumabNovel optionGravisMyositisDeactivation signalsInhibitorsMalignancyTherapyTumors